ChromaDex’s Niagen shows positive results in Alzheimer’s
ChromaDex (CDXC) announced results from its collaborative research agreement with the NIA and NIH which appear in the Feb. 5 issue of Proceedings of the National Academy of Sciences showing that Niagen nicotinamide riboside prevented neurological damage and improved cognitive and physical function in a new mouse model of Alzheimer’s disease that more closely resembles human AD than other mouse models.
These findings arrive a few months after results demonstrating that AD mice treated with NR had lower levels of amyloid deposits, improved mitochondrial energy production and improved memory in his paper, in the journal Nature.
Researchers found that the mice receiving Niagen had reduced tangles in their brains, higher neuroplasticity, less DNA damage, increased production of new neurons from neuronal stem cells, and lower levels of neuronal damage and death.
In fact, in the area of the brain which typically becomes damaged in individuals with dementia, Niagen appeared to either clear existing DNA damage or prevent it from spreading.
The study suggests that NR enters the brain and boosts cellular NAD+ levels when administered orally. The research team attributes the observed physical and cognitive benefits to the rejuvenating effect NR had on stem cells in both muscle and brain tissue.
CDXC closed at $4.82.
STOCKWINNERS
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
